Also known as Gleevec
Imatinib (INN), marketed by Novartis as Gleevec (U.S.) or Glivec (Europe/Australia/Latin America), is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Like all tyrosine-kinase inhibitors, imatinib works by preventing a tyrosine kinase enzyme, in this case BCR-Abl, from phosphorylating subsequent proteins and initiating the signaling cascade necessary for cancer development, thus preventing the growth of cancer cells and leading to their death by apoptosis. Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy—only cancer cells are killed through the drug's action. In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.Source: Wikipedia
Estimated Total Cost: $4098.95 for an average of 28 days supply
Patients are most commonly prescribed imatinib to treat leukemia, metastatic cancer, blastomycosis, and rabies.
Patients taking imatinib most commonly experience side effects like nausea, fatigue, and cramps and spasms.
|Cramps and spasms|
|Shortness of breath|
|Alopecia (Loss Of Hair)|
|Itching of skin|
|Itching of unknown cause|
|Gastrointestinal hemorrhage (GI Bleeding)|